| Shuang Zhang,Jingjing Liu,Hui Li,Ying Cheng. Anti-angiogenesis in lung cancer therapy: the shore and the other shore. Oncol Transl Med, 2015, 1: 15-19. |
| 肺癌抗肿瘤血管药物治疗：此岸与彼岸 |
| Anti-angiogenesis in lung cancer therapy: the shore and the other shore |
| Received:December 31, 2014 Revised:February 02, 2015 |
| DOI：10.1007/s10330-014-0050-z |
| 中文关键词: 血管生成；非小细胞肺癌 |
| 英文关键词: angiogenesis; non-small cell lung cancer (NSCLC) |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Shuang Zhang | Department of Thoracic Oncology,Jilin Provincial Cancer Hospital | zhangshuangphy@126.com | | Jingjing Liu | Department of Thoracic Oncology,Jilin Provincial Cancer Hospital | jingjingstone@126.com | | Hui Li | Department of Thoracic Oncology,Jilin Provincial Cancer Hospital | zhangshuangphy@126.com | | Ying Cheng* | Department of Thoracic Oncology,Jilin Provincial Cancer Hospital | jl.cheng@163.com |
|
| Hits: 9197 |
| Download times: 11876 |
| 中文摘要: |
| 血管生成是肿瘤发生发展的重要事件，近年来，肿瘤血管生成的基础和临床研究取得了不断的进展，但仍然有许多问题没有解决。因此我们总结了最近在非小细胞肺癌领域完成的抗血管治疗的相关临床研究，同时也讨论了未来抗血管治疗面临的挑战。 |
| 英文摘要: |
| Angiogenesis is known to be an important event in tumor growth. In preclinical and clinical researches, anti-angiogenesis therapy has made great progress, but there are still many problems for future anti-angiogenesis therapy. Here, we review recently completed clinical trials of emerging antiangiogenic agents in patients with non-small cell lung cancer (NSCLC) and discuss the challenges of anti-angiogenic therapy. |
|
View Full Text
Download reader HTML全文 |
| Close |